Study #2020-1212
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Angiosarcoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Sintilimab
Description
This phase II trial evaluates the effect of sintilimab in treating patients with angiosarcoma that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as sintilimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving sintilimab may help to control angiosarcoma.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma
Study phase:
Phase II
Physician name:
Vinod Ravi
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-877-934-6089
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.